for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Takeda Pharmaceutical Co Ltd

4502.T

Latest Trade

4,449.00JPY

Change

19.00(+0.43%)

Volume

3,374,500

Today's Range

4,442.00

 - 

4,486.00

52 Week Range

3,401.00

 - 

4,822.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4,430.00
Open
4,466.00
Volume
3,374,500
3M AVG Volume
105.78
Today's High
4,486.00
Today's Low
4,442.00
52 Week High
4,822.00
52 Week Low
3,401.00
Shares Out (MIL)
1,557.75
Market Cap (MIL)
6,983,261.00
Forward P/E
-25.15
Dividend (Yield %)
4.06

Next Event

Q3 2020 Takeda Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Takeda Canada Says TAKHZYRO Gets Positive Recommendation From CADTH's CDEC For Routine Prevention Of HAE Attacks

Finch Therapeutics & Takeda Expand Collaboration To Develop Microbiome Therapeutics

Takeda And MD Anderson Announce Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Industry

Major Drugs

Contact Info

4F, 2-1-1, Nihombashihon-cho

+81.3.32782111

https://www.takeda.com/

Executive Leadership

Masahiro Sakane

Independent Chairman of the Executive Board

Christophe Weber

President, Chief Executive Officer, Representative Director

Constantine Saroukos

Chief Financial Officer, Director

Masato Iwasaki

President of Japan Pharma Business Unit, President of Subsidiary, Director

Andrew S. Plump

President of Research & Development, Director

Key Stats

1.85 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

1.7K

2018

1.8K

2019

2.1K

2020(E)

3.3K
EPS (JPY)

2017

147.150

2018

239.350

2019

113.500

2020(E)

-177.628
Price To Earnings (TTM)
138.00
Price To Sales (TTM)
2.43
Price To Book (MRQ)
1.42
Price To Cash Flow (TTM)
12.65
Total Debt To Equity (MRQ)
103.27
LT Debt To Equity (MRQ)
99.74
Return on Investment (TTM)
0.22
Return on Equity (TTM)
0.18

Latest News

Latest News

Longer-term data fail to clear concern over Takeda's dengue vaccine

An additional six months of data from a late-stage trial of Takeda Pharmaceutical Co's experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group, researchers said on Saturday.

Stada buys Takeda drug bundle to boost Russia business

Germany's Stada <STAGn.D> on Tuesday agreed to purchase over-the-counter and prescription drugs units from Japan's largest drugmaker Takeda <4502.T> for $660 million (£512 million), part of two deals that boost its Russian and Eastern European footprint.

Takeda to sell portfolio of select drugs for $660 million

Takeda Pharmaceutical Co Ltd said on Tuesday it would sell some of its over-the-counter and prescription drugs to Germany's STADA Arzneimittel AG for a total value of $660 million.

Japanese drugmaker Takeda cuts full-year loss forecast

Takeda Pharmaceutical <4502.T> trimmed its full-year loss forecast on strong sales of its core drugs and progress in its consolidation with Shire Plc.

Japan's Takeda cuts full year loss forecast

Takeda Pharmaceutical Co Ltd said on Thursday its half year profit fell by 70%, and the company trimmed its estimate for a full-year loss.

Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino

Japan's Takeda Pharmaceutical Co Ltd <4502.T> said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million.

Takeda sells Mideast, Africa drugs to Switzerland's Acino for around $200 mln

Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million.

Fresenius Medical Care appoints Takeda executive Helen Giza as CFO

German dialysis specialist Fresenius Medical Care <FMEG.DE> has hired Helen Giza from Japan's Takeda Pharmaceutical <4502.T> as its new finance chief, replacing Mike Brosnan.

Takeda kicks off sale of Western European drugs - sources

Japan's Takeda Pharmaceutical Co <4502.T> has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Olympics - Japan's Yamashita appointed chief as Takeda resigns in graft probe

The Japanese Olympic Committee (JOC) picked former Olympic judo champion Yasuhiro Yamashita as its new chief after the resignation of Tsunekazu Takeda, who is being investigated for suspected corruption related to the Tokyo 2020 bid.

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Japan's Takeda expects binding offers for Latam business by end of May: sources

Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

Japan's Takeda forecasts surprise annual loss on Shire-related costs

Takeda Pharmaceutical Co forecast an unexpected operating loss for the current year due to costs associated with the $59 billion purchase of Shire Plc, providing the first set of financial results of the combined firm.

Japan's Takeda expects annual loss on Shire deal

Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

Novartis buys dry eye drug from Takeda for up to $5.3 billion

Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.

Novartis buys Takeda's dry eye drug for $3.4 bln

Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.

BRIEF-Takeda says To Sell Xiidra To Novartis For Up To $5.3 Bln

* TAKEDA SIMPLIFIES PORTFOLIO AND ACCELERATES DELEVERAGING THROUGH TWO DIVESTITURES

BRIEF-Novartis Says Entered Into Agreement With Takeda Pharmaceutical To Acquire Xiidra 5 pct Worldwide

* REG-NOVARTIS TO ACQUIRE XIIDRA®, EXPANDING FRONT-OF-EYE PORTFOLIO AND STRENGTHENING LEADERSHIP IN EYE CARE

Japan's Takeda invites Brazilian pharmaceutical firms to bid for Latam business: sources

Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.

Japan's Takeda invites Brazilian pharmaceutical firms to bid for Latam business- sources

Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up